Q3 2025 Alnylam Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Alnylam Pharmaceuticals Inc (ALNY) reported strong financial performance with total product revenues of $851 million, representing a 103% growth year-over-year.
- The TTR franchise, particularly driven by the AMVUTTRA launch, showed significant growth with a 135% increase in revenues year-over-year.
- The company has initiated two new Phase 3 trials, ZENITH for zilebesiran in hypertension and TRITON PN for icrisiran in hATTR-PN, indicating robust pipeline advancement.
- Alnylam Pharmaceuticals Inc (ALNY) increased its total net product revenue guidance for 2025 to a range of $2.95 billion to $3.05 billion, reflecting confidence in ongoing product launches.
- The company maintains a strong cash position with $2.7 billion in cash, cash equivalents, and marketable securities, providing financial stability and flexibility.
- Gross margin on product sales decreased to 77% from 80% in the previous year, primarily due to increased royalties on AMVUTTRA.
- Non-GAAP R&D expenses increased by 23% year-over-year, driven by costs associated with multiple Phase 3 clinical studies.
- Non-GAAP SG&A expenses rose by 35% compared to last year, reflecting increased headcount and investments for the AMVUTTRA launch.
- The company is facing a subpoena from the US Attorney's office related to government price reporting, which could pose legal and financial risks.
- Ex-US market contributions remain modest, with significant revenue growth expected only in mid to late 2026, indicating potential delays in international expansion.
Good morning, ladies and gentlemen, and welcome to the Alnylam Pharmaceuticals 3Q 2025 earnings conference call. (Operator Instructions) Also note that this call is being recorded on Thursday, October 30, 2025.
And now I would like to turn the conference over to management. Please go ahead.
Good morning. I'm Christine Akinc, Chief Corporate Communications Officer at Alnylam. With me today are Yvonne Greenstreet, Chief Executive Officer; Tolga Tanguler, Chief Commercial Officer; Pushkal Garg, Chief Research and Development Officer; and Jeff Poulton, Chief Financial Officer.
For those of you participating via conference call, the accompanying slides can be accessed by going to the Events section of the Investors page of our website, investors.alnylam.com/events. During today's call, as outlined on slide 2, Yvonne will offer some introductory remarks and provide general context.
To will provide an update on our global commercial progress. Pushkal will
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
